Core Insights - The article emphasizes the importance of understanding the science behind biotech investments and the potential pitfalls associated with them [2]. Group 1 - The author has a PhD in biochemistry and extensive experience analyzing clinical trials and biotech companies, highlighting the need for informed investment decisions in this sector [2]. - The mission is to educate investors on the complexities of biotech businesses to prevent losses from uninformed decisions [2]. Group 2 - The article does not provide specific investment recommendations or advice, indicating a focus on education rather than direct investment guidance [3]. - It clarifies that past performance is not indicative of future results, reinforcing the need for due diligence in investment choices [3].

Financial Data and Key Metrics Changes - TriSalus reported total revenue of $7.3 million for Q3 2024, reflecting a 42% growth compared to the same period in 2023 [6][44] - Year-to-date revenue stands at $21.2 million, reflecting a 66% growth compared to the first nine months of the previous year [45] - The company maintained a gross margin of 86%, consistent with year-to-date margins and up from 84% for the same period in 2023 [47] - Operating losses for Q3 were negative $8.7 million, an improvement from $18.8 million in Q3 2023 [51] Business Line Data and Key Metrics Changes - The company added 42 net new hospital accounts in Q3, with utilization rising to 15.3 units per account, up from 13.5 units per account in Q3 2023 [45] - The launch of TriNav Large and TriGuide Catheter is underway, expanding the product portfolio to address embolization challenges for complex patients [11] Market Data and Key Metrics Changes - The addressable market for TriNav technology is now over $1 billion, with an incremental market opportunity of $400 million from the new procedure for multinodular goiters [20][19] - The company expects to have approximately 50 commercial personnel by the end of the year to establish comprehensive coverage of high procedure markets [7] Company Strategy and Development Direction - TriSalus aims for sustained growth of 50% annually, driven by expanding market penetration and innovative product launches [5][41] - The company plans to become EBITDA positive in 2025, focusing on revenue growth and operational discipline [40][53] - The DELIVER clinical program is designed to demonstrate enhanced efficacy and safety across a broad spectrum of complex patients [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving over 50% revenue growth in 2025, supported by the successful rollout of TriNav Large and TriNav 2.0 [57] - The company is actively exploring strategic partnerships to advance the nelitolimod program, particularly for uveal melanoma liver metastases [35] Other Important Information - The company plans to draw $10 million from the OrbiMed debt facility early in Q1 2025 to sustain operations through 2025 [52] - The company is submitting for a Category 3 reimbursement code in February 2025, with expectations for approval in mid-2025 [64] Q&A Session Summary Question: Guidance for 2025 and assumptions - Management indicated that the sales force is primarily targeted in the taste and tear market, with early usage in other areas being minimal [60] Question: Advancing nelitolimod and partnership plans - Management stated that they are open to partnerships for uveal melanoma but will not pursue formal programs for other indications at this time [62] Question: Utilization and growth expectations for 2025 - Management expects average utilization to increase to 17.5 units per account, with significant growth from new accounts [67] Question: Multinodular goiters treatment paradigm - Management highlighted the risks associated with surgery and the advantages of their technology in treating multinodular goiters [70][72] Question: 2024 guidance and monthly cadence - Management noted unusual monthly utilization patterns, with a significant increase in September compared to previous months [78] Question: Cash burn and expense reductions - Management explained that cash burn is expected to decrease significantly due to reduced clinical costs and administrative expenses [82] Question: Efficacy of nelitolimod in pancreatic trials - Management is analyzing extensive tissue samples to assess the efficacy of nelitolimod and will provide updates in mid-2025 [85] Question: Competitive landscape for TriNav - Management expressed confidence in their unique technology and noted a lack of direct competitors in the liver and pancreatic markets [90][91]

Financial Performance - Revenue increased by $2.2 million, or 41.5%, for the three months ended September 30, 2024, compared to the same period in 2023, primarily due to increased sales of TriNav[200]. - Revenue increased by $8.4 million, or 65.5%, for the nine months ended September 30, 2024, compared to the same period in 2023, primarily due to increased sales of TriNav[209]. - Gross profit increased by $1.7 million, or 37.8%, for the three months ended September 30, 2024, while gross margin decreased to 86.3% from 88.7%[202]. - Gross profit increased by $7.5 million, or 69.8%, for the nine months ended September 30, 2024, with gross margin percentage rising to 86.4% from 84.2%[211]. - The company reported a net loss available to common stockholders of $2.4 million for the three months ended September 30, 2024[199]. - Net cash used in operating activities was $35.1 million for the nine months ended September 30, 2024, compared to $41.4 million for the same period in 2023[223]. - Cash and cash equivalents were approximately $11.3 million at September 30, 2024, with significant net losses expected to continue due to ongoing investments in R&D and marketing[221]. Expenses - Cost of goods sold rose by $0.4 million, or 70.5%, for the three months ended September 30, 2024, attributed to higher production volumes[200]. - Research and development expenses decreased by $5.3 million, or 55.6%, for the three months ended September 30, 2024, mainly due to reduced clinical trial expenses[203]. - Sales and marketing expenses increased by $1.4 million, or 30.9%, for the three months ended September 30, 2024, driven by higher payroll and travel expenses[204]. - General and administrative expenses decreased by $4.3 million, or 47.6%, for the three months ended September 30, 2024, primarily due to prior period expenses related to the Business Combination[205]. - Research and Development expenses decreased by $7.3 million, or 33.3%, for the nine months ended September 30, 2024, mainly due to reduced clinical trial expenses[212]. - Sales and marketing expenses increased by $7.4 million, or 64.7%, for the nine months ended September 30, 2024, driven by higher payroll and travel expenses[213]. - General and administrative expenses decreased by $4.2 million, or 23.9%, for the nine months ended September 30, 2024, primarily due to prior period legal and consulting expenses not repeated this year[214]. Capital and Financing - TriSalus reported a total of $12.4 million raised from the sale of 1,874,867 shares of common stock under the SEPA during the nine months ended September 30, 2024[172]. - The OrbiMed Credit Agreement provides for up to $50.0 million in senior secured term debt, with an initial commitment of $25.0 million made available on April 30, 2024[173]. - The Warrant Exchange Offering resulted in the issuance of 2,110,366 shares of common stock in exchange for tendered warrants[177]. - The company anticipates needing to raise additional capital to fund operations and execute its long-term business strategy[221]. - The company may require additional capital in the near term through securities offerings, debt financings, collaborations, or licensing arrangements[233]. Clinical and Product Development - The TriNav Infusion System received a permanent HCPCS code effective January 1, 2024, allowing for reimbursement for procedures involving the device[164]. - The company launched the TriNav LV Infusion System and TriGuide Guiding Catheter to expand its addressable liver embolization market[165]. - TriSalus is currently conducting Phase 1 and Phase 1b clinical trials for nelitolimod, with data from the pancreatic cancer trial expected in 2025[167]. - The company initiated the DELIVER program to evaluate the TriNav system in complex patient populations, aiming to validate previous clinical studies[180]. - The TPT payment program from CMS expired on December 31, 2023, but a new HCPCS code was granted for TriNav, which may affect future revenue[171]. Internal Controls and Compliance - The company has identified material weaknesses in internal control over financial reporting, which could affect the accuracy and timeliness of financial results[242]. - A remediation plan has been developed, including hiring four additional trained resources to address the identified weaknesses[244]. - As of September 30, 2024, the company's disclosure controls and procedures were deemed not effective at the reasonable assurance level[241]. - The company intends to monitor the effectiveness of its remediation plan but cannot estimate the timeline for completion[245]. Legal and Regulatory Matters - The company is not currently a party to any material legal proceedings that could adversely affect its business[249]. - As of September 30, 2024, there is substantial doubt regarding the company's ability to continue as a going concern[234]. - The company's contractual obligations include lease obligations of $2.5 million as of September 30, 2024[235]. - The company has paid Dynavax $12 million and may owe up to an additional $158 million upon achieving certain milestones related to nelitolimod[236].

Financial Performance - Reported Q3 2024 revenues of $7.3 million, representing a 42% year-over-year increase, and nine-month revenues of $21.2 million, up 66% year-over-year[1] - Revenue for the three months ended September 30, 2024, was $7,349,000, a 41.5% increase from $5,193,000 for the same period in 2023[20] - Gross profit for the nine months ended September 30, 2024, was $18,283,000, compared to $10,767,000 for the same period in 2023, representing a 70% increase[20] - Operating losses decreased to $8.7 million in Q3 2024 from $18.6 million in Q3 2023, due to increased sales and reduced expenses[12] - Net losses available to common stockholders were $2.4 million for Q3 2024, compared to $1.4 million in Q3 2023[13] - Net loss attributable to common stockholders for the three months ended September 30, 2024, was $3,202,000, compared to a loss of $1,883,000 for the same period in 2023[20] Market Expansion - Launched the TriNav® LV Infusion System and TriGuide™ Guiding Catheter, expanding access to the $375 million liver embolization market[1] - Initiated the PROTECT registry trial for treating multinodular goiters, potentially expanding the addressable market by $400 million[3] - The total addressable market is projected to exceed $1 billion in the U.S. with the new procedures utilizing the TriNav system[6] Guidance and Future Outlook - Provided 2025 guidance expecting over 50% annual sales growth and a reduction in operating expenses by over 20%[3] - Cash and cash equivalents totaled $11.3 million as of September 30, 2024, with expectations of positive cash flow in H2 2025[14] Operational Efficiency - Gross margins for Q3 2024 were 86%, compared to 89% in Q3 2023, attributed to increased factory volumes and operational efficiency[11] - Research and development expenses for the three months ended September 30, 2024, were $4,219,000, down from $9,506,000 in the same period of 2023, a decrease of 55.7%[20] - Sales and marketing expenses increased to $6,138,000 for the three months ended September 30, 2024, compared to $4,689,000 in the same period of 2023, an increase of 30.9%[20] Balance Sheet Highlights - Total assets as of September 30, 2024, were $27,477,000, an increase from $24,598,000 as of December 31, 2023[21] - Total liabilities decreased to $47,911,000 as of September 30, 2024, from $51,663,000 as of December 31, 2023[21] - The accumulated deficit increased to $(269,441,000) as of September 30, 2024, from $(249,504,000) as of December 31, 2023[22] - Cash and cash equivalents were $11,288,000 as of September 30, 2024, compared to $11,777,000 as of December 31, 2023[21] - The company reported a weighted average of 26,501,597 common shares outstanding for the three months ended September 30, 2024, compared to 13,173,422 shares for the same period in 2023[20]

Financial Data and Key Metrics Changes - TriSalus achieved revenue of $7.4 million in Q2 2024, marking a 60% increase compared to Q2 2023, and $13.8 million for the first half of 2024, representing an 82% growth year-over-year [19][20] - The company reported a gross margin of 88% in Q2 2024, up from 83% in Q2 2023, indicating improved operational efficiencies [20] - Operating losses decreased to $8.2 million in Q2 2024 from $11.4 million in Q2 2023, attributed to increased sales and lower R&D costs [22] Business Line Data and Key Metrics Changes - TriNav revenues grew by 60% year-over-year, driven by reimbursement, clinical data, and sales force expansion [4][19] - The company captured 27 new hospital accounts, with account utilization increasing from 12.4 units per account in Q2 2023 to 15.2 units in Q2 2024 [19] Market Data and Key Metrics Changes - The DELIVER program targets complex patient populations, including those with multinodular goiter, with an estimated addressable market of up to 50,000 patients [27] - The company is focusing on expanding its presence in the interventional radiology community to enhance the adoption of its TriNav technology [4] Company Strategy and Development Direction - TriSalus is committed to advancing its DELIVER program, which includes a series of investigator-initiated clinical trials to gather real-world data on the TriNav system [5][6] - The company plans to launch the TriNav Large system later in 2024 and aims to achieve over 50% revenue growth for the year [8][20] - The focus remains on enhancing patient safety and efficacy through innovative therapeutic delivery methods [6][8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving over 50% top-line revenue growth and approaching positive EBITDA by late 2024, excluding clinical costs [20][24] - The management team highlighted the importance of strategic resource allocation in deciding the future of clinical trials, particularly for PERIO-02 [31] Other Important Information - The company closed a debt financing facility in April, securing $25 million, with an additional $25 million available based on revenue thresholds [23] - TriSalus ended the quarter with $16.5 million in cash and cash equivalents, providing a runway through the end of 2025 [24] Q&A Session Summary Question: Context on patient numbers for DELIVER program - The initial patient population includes those with multinodular goiter, with an estimated total addressable market of up to 50,000 patients [27] Question: Criteria for moving forward with PERIO-01 and PERIO-03 - The decision will be based on significant treatment effects, market size, and regulatory feasibility, with announcements expected in Q4 [27][31] Question: Future pursuit of PERIO-02 - The data from PERIO-02 was encouraging, but resource allocation decisions influenced the current strategy; future pursuit may depend on available resources [31] Question: Pricing for TriNav Large and details on PROTECT - TriNav Large will be priced identically to the regular TriNav, and the PROTECT program will utilize bland embolization techniques [33][34]

Financial Performance - Reported revenues of $7.4 million in Q2 2024, up 60% compared to the same period in 2023, and $13.8 million for the six months ended June 30, 2024, up 82% year-over-year[1] - Gross margin improved to 88% in Q2 2024 and 86% for the six months ended June 30, 2024, compared to 83% and 81% in the prior year periods[1] - Revenue for Q2 2024 reached $7,364,000, a 59.8% increase from $4,612,000 in Q2 2023[15] - Gross profit for the first half of 2024 was $11,938,000, compared to $6,162,000 in the same period of 2023, reflecting a 93.5% increase[15] - Net loss attributable to common stockholders for Q2 2024 was $5,133,000, down from $15,996,000 in Q2 2023, representing a 67.8% improvement[15] - Operating losses reduced to $8.2 million in Q2 2024 from $11.4 million in Q2 2023, and $19.9 million for the six months ended June 30, 2024, down from $21.6 million in the prior year[7] - Net losses available to common stockholders were $4.3 million in Q2 2024, significantly improved from $14.0 million in Q2 2023[8] - The basic and diluted loss per share for Q2 2024 was $0.21, compared to $35.84 for the same period in 2023[10] - The company reported a loss from operations of $8,174,000 in Q2 2024, an improvement from a loss of $11,434,000 in Q2 2023[15] Capital and Financing - Closed up to $50 million of debt financing with OrbiMed to support TriNav system growth initiatives, with $25 million borrowed at closing[5] - The company completed a warrant exchange offer, simplifying its capital structure and reducing potential dilution[9] - Total current assets increased to $27,941,000 as of June 30, 2024, up from $20,862,000 at the end of 2023, a growth of 33.5%[16] - Cash and cash equivalents rose to $16,481,000 in Q2 2024, compared to $11,777,000 at the end of 2023, an increase of 40.0%[16] - Total liabilities increased to $56,580,000 as of June 30, 2024, compared to $51,663,000 at the end of 2023, a rise of 9.5%[16] Research and Development - Anticipates reporting data from phase 1 trials of nelitolimod in Q4 2024 for uveal melanoma liver metastases and locally advanced pancreatic cancer[1] - The company plans to launch the "DELIVER" Program in Q3 2024 to expand the addressable market using the TriNav® Infusion System[1] - The DELIVER program aims to validate the PEDD technology's effectiveness in complex patient populations and enhance treatment outcomes[3] - Research and development expenses decreased to $10,523,000 in the first half of 2024 from $12,504,000 in 2023, a reduction of 15.9%[15] Shareholder Information - The weighted average common shares outstanding for Q2 2024 were 23,903,659, significantly higher than 446,287 in Q2 2023[15] - Interest income increased to $97,000 in Q2 2024 from $36,000 in Q2 2023, a growth of 169.4%[15]

Financial Performance - Revenue increased by $2.8 million, or 59.7%, for the three months ended June 30, 2024, compared to the same period in 2023, primarily due to increased sales of TriNav[175]. - Gross profit increased by $2.6 million, or 68.0%, for the three months ended June 30, 2024, with gross margin rising to 87.6% from 83.3% in the same period last year[176]. - Revenue increased by $6.2 million, or 82.0%, for the six months ended June 30, 2024, compared to the same period in 2023, primarily due to increased sales of TriNav[188]. - Gross profit increased by $5.8 million, or 93.7%, for the six months ended June 30, 2024, with gross margin percentage rising to 86.4% from 81.1%[188]. - The net loss attributable to common stockholders was $5.1 million for the three months ended June 30, 2024, compared to a net loss of $15.996 million in the same period of 2023[173]. - The company incurred net losses of $17.6 million for the six months ended June 30, 2024, and expects to continue incurring losses due to ongoing investments in R&D and marketing[195]. Research and Development - The DELIVER program aims to evaluate the TriNav system across complex patient populations, with the first clinical study named "PROTECT" focusing on thyroid disease[154][155]. - TriSalus is currently in Phase 1 human trials for nelitolimod, with no guarantee of favorable data or FDA approval[144]. - R&D expenses decreased by $2.2 million, or 32.2%, for the three months ended June 30, 2024, mainly due to reduced clinical trial expenses related to nelitolimod[178]. - R&D expenses decreased by $2.0 million, or 15.8%, primarily due to a reduction in clinical trial expenses related to nelitolimod[189]. Capital and Financing - TriSalus reported a total consideration of $220.0 million for the Business Combination, payable in approximately 22,000,000 shares of MTAC common stock[142]. - The OrbiMed Credit Agreement provides for up to $50.0 million in senior secured term debt, with an initial commitment of $25.0 million borrowed on April 30, 2024[146][147]. - The company raised $6.7 million from the sale of 750,000 shares of common stock under the SEPA during the six months ended June 30, 2024[196]. - The company anticipates needing additional capital to fund operations and execute its long-term business strategy, with substantial doubt regarding its ability to continue as a going concern as of June 30, 2024[206]. Expenses - Sales and marketing expenses increased by $2.5 million, or 71.9%, for the three months ended June 30, 2024, driven by higher payroll and travel expenses due to increased headcount[179]. - General and administrative expenses decreased by $0.9 million, or 19.2%, for the three months ended June 30, 2024, primarily due to prior period legal and consulting expenses not repeated this year[180]. - Sales and marketing expenses increased by $6.0 million, or 88.3%, driven by higher payroll and travel expenses due to increased headcount[189]. Liabilities and Obligations - As of June 30, 2024, the company has lease obligations totaling $1.5 million for its principal administrative and production facility and other office spaces[207]. - The company has paid Dynavax $12 million as of June 30, 2024, with potential additional payments of up to $158 million upon achieving certain development and regulatory milestones for nelitolimod[208]. - Subject to marketing approval for nelitolimod, the company may also pay up to $80 million upon achieving certain commercial milestones[208]. - The Dynavax Agreement includes low double-digit royalties based on future net sales of products containing nelitolimod, with potential reductions of up to 50% under certain circumstances[208]. Other Financial Information - The expiration of the TPT payment program on December 31, 2023, may impact TriNav sales and revenue generation[144]. - The company has yet to generate sufficient revenues to drive positive cash flows from operations[141]. - Interest income increased by $0.1 million, or 169.4%, for the three months ended June 30, 2024, attributed to additional interest from investments in short-term money market funds[181]. - Interest expense increased by $0.9 million for the three months ended June 30, 2024, due to interest incurred on the OrbiMed loan[182]. - The change in fair value of SEPA, warrant, and revenue base redemption liabilities resulted in a loss of $9.0 million for the three months ended June 30, 2024, compared to a gain of $1.1 million in the same period last year[184]. - The change in fair value of contingent earnout liability resulted in a gain of $13.7 million for the three months ended June 30, 2024, due to the lower market price of the underlying common stock[185]. - A gain of $9.7 million was recorded for the change in fair value of earnout liabilities for the six months ended June 30, 2024, due to a lower market price of the underlying common stock[193]. - There are no off-balance sheet financing arrangements or relationships with unconsolidated entities as of the reporting period[209]. - There have been no significant changes in critical accounting policies during the six months ended June 30, 2024, compared to the previous year[210].

Core Viewpoint - TriSalus Life Sciences, Inc. (TLSI) is a device manufacturer focused on organ-targeted therapy delivery mechanisms, with ongoing efforts to develop its own drug to complement its devices, presenting a potential investment opportunity as the market cap has declined significantly [1][13]. Pipeline Updates - TLSI's platform aims to improve tumor uptake of chemotherapy agents in organ-restricted cancers, particularly liver and pancreatic cancers, with optimism surrounding its use in liver metastases from uveal melanoma [2]. - The company is developing nelitolimod (formerly SD-101), a TLR9 activator, which is being evaluated in various solid tumors, including liver metastases and primary liver cancers [3]. Clinical Data - At the Annual Meeting of the Society of Interventional Radiology, the PERIO-03 study demonstrated the feasibility of delivering nelitolimod via pancreatic retrograde venous infusion in 5 patients without immediate complications [4]. - The ASCO Annual Meeting presented more promising data from the PERIO-02 study, where nelitolimod achieved disease control in all 3 patients treated, with no safety concerns noted across 23 patients [5]. Financial Overview - As of the latest quarterly filing, TLSI reported $13.2 million in current assets, including $4.0 million in cash, with a net loss of $13.2 million after operational expenses of $11.7 million [7]. - The company secured $50 million in financing from OrbiMed, extending its cash runway to just over one year, with an additional potential $25 million based on revenue targets [8]. Strengths and Risks - TLSI has seen rapid sales growth from its approved devices, which supports ongoing drug development efforts and provides some financial stability [9]. - Early clinical data for nelitolimod is encouraging, with no major safety concerns reported, although caution is advised due to the small patient cohorts [10]. - Despite securing financing, TLSI's cash runway remains a concern, with quarterly sales doubling year-over-year but still facing significant cash burn [11][12]. Bottom Line Summary - TLSI's market cap has dropped to around $150 million, making it appear more attractive given its two marketed devices generating growing sales, although cash concerns persist [13].

Financial Data and Key Metrics Changes - Company reported a remarkable 116% growth in revenues, reaching $6.5 million, driven solely by the success of the TriNav device in the U.S. This represents the highest quarterly sales in the company’s history [9][15]. - Gross margin improved to 85% in Q1 2024, up from 78% in Q1 2023, attributed to increased factory volumes and operational efficiencies [17][25]. - Operating losses for Q1 2024 totaled $11.7 million, compared to $10.1 million in Q1 2023, primarily due to higher operating expenses in sales and marketing, R&D, and general administrative expenses [37]. Business Line Data and Key Metrics Changes - The growth in revenue was entirely from the sale of TriNav, with the company capturing 32 net new hospital accounts, exceeding internal projections due to pent-up demand [15][16]. - Account utilization increased to 14.5 units per account compared to 11.2 units in Q1 2023, indicating stronger adoption of the TriNav device [16]. Market Data and Key Metrics Changes - The company has achieved a compound annualized growth rate of approximately 50% since the launch of the TriNav product in 2020, with expectations for continued growth over 50% in 2024 [26]. Company Strategy and Development Direction - The company is positioning TriNav to become the standard-of-care for complex patients and is implementing educational and reimbursement support programs to facilitate adoption [12]. - The launch of TriNav Large is anticipated in the second half of the year, with ongoing clinical trials for nelitolimod expected to yield promising results [12][13]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving over 50% top-line revenue growth and advancing the pipeline, supported by recent positive developments in reimbursement and robust clinical data [14]. - The company is focused on pursuing indications with low competitive environments and significant treatment effects, with a comprehensive evaluation of clinical data expected in the third quarter [27]. Other Important Information - The company closed a debt financing facility in April, borrowing $25 million with an additional $25 million available, which is expected to provide sufficient runway to fund operations through the end of 2025 [38]. - General and administrative expenses increased by 30% compared to Q1 2023, primarily due to costs associated with becoming a public company [20]. Q&A Session Summary Question: Upcoming data readouts for nelitolimod and their impact on future decisions - Management is waiting for recently enrolled patients to reach the six-month mark for a comprehensive evaluation, with plans to pursue indications based on competitive environment and treatment effect [27]. Question: Preparation efforts for the commercial launch of TriNav Large - The company has conducted extensive market evaluations and validated the need for a larger size of TriNav, with plans to launch in the fourth quarter [34][42].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number 001-39813 TRISALUS LIFE SCIENCES, INC. Registrant's telephone number, including area code N/A (Forme ...